dl-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA₂ synthesis and phosphodiesterase

References

• Jennings LK. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009;102:248–257
   PubMed Web of Science ®Google Scholar
• Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010;30:2341–2349
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 2013;382:614–623
   PubMed Web of Science ®Google Scholar
• Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: A review. JAMA 2013;310:189–198
   PubMed Web of Science ®Google Scholar
• Peng Y, Zeng X, Feng Y, Wang X. Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in rats. J Cardiovasc Pharmacol 2004;43:876–881
   PubMed Web of Science ®Google Scholar
• Xu J, Wang Y, Li N, Xu L, Yang H, Yang Z. L-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia. Neuropharmacology 2012;62:2424–2429
   PubMed Web of Science ®Google Scholar
• Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. J Neurosci 2010;30:8180–8189
   PubMed Web of Science ®Google Scholar
• Cui LY, Zhu YC, Gao S, Wang JM, Peng B, Ni J, Zhou LX, He J, Ma XQ. Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: A randomized, double-blind trial. Chin Med J (Engl) 2013;126:3405–3410
   PubMed Web of Science ®Google Scholar
• Niu C, Liang C, Guo J, Cheng L, Zhang H, Qin X, Zhang Q, Ding L, Yuan B, Xu X, et al. Downregulation and growth inhibitory role of FHL1 in lung cancer. Int J Cancer 2012;130:2549–2556
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Ogle M, Zhou X, Song M, Yu SP, Wei L. DL-3-n-butylphthalide prevents neuronal cell death after focal cerebral ischemia in mice via the JNK pathway. Brain Res 2010;1359:216–226
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Li J, Wang XL. 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther 2006;317:973–979
   PubMed Web of Science ®Google Scholar
• Xu HL, Feng YP. Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats. Yao Xue Xue Bao 2001;36:329–333
   PubMedGoogle Scholar
• Lu XL, Luo D, Yao XL, Wang GL, Liu ZY, Li ZX, Li W, Chang FJ, Wen L, Lee SM, et al. dl-3n-Butylphthalide promotes angiogenesis via the extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase/Akt-endothelial nitric oxide synthase signaling pathways. J Cardiovasc Pharmacol 2012;59:352–362
   PubMed Web of Science ®Google Scholar
• Zhang L, Lu L, Chan WM, Huang Y, Wai MS, Yew DT. Effects of DL-3-n-butylphthalide on vascular dementia and angiogenesis. Neurochem Res 2012;37:911–919
   PubMed Web of Science ®Google Scholar
• Liao SJ, Lin JW, Pei Z, Liu CL, Zeng JS, Huang RX. Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP. Brain Res 2009;1289:69–78
   PubMed Web of Science ®Google Scholar
• Zhang SH, Zhang Y, Shen J, Zhang S, Chen L, Gu J, Mruk JS, Cheng G, Zhu L, Kunapuli SP, Ding Z. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A signaling and phosphodiesterase. J Thromb Haemost 2013;11:1855–1866
   PubMed Web of Science ®Google Scholar
• Hu L, Fan Z, Du H, Ni R, Zhang S, Yin K, Ye J, Zhang Y, Wei X, Zhang X, et al. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y(1)(2) receptor and phosphodiesterase. Thromb Haemost 2011;106:1203–1214
   PubMed Web of Science ®Google Scholar
• Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, Jin J, Zhang J, Liu J, Zhang X, et al. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 2010;104:845–857
   PubMed Web of Science ®Google Scholar
• Shankar H, Murugappan S, Kim S, Jin J, Ding Z, Wickman K, Kunapuli SP. Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood 2004;104:1335–1343
   PubMed Web of Science ®Google Scholar
• Ding Z, Bynagari YS, Mada SR, Jakubowski JA, Kunapuli SP. Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists. J Thromb Haemost 2009;7:232–234
   PubMed Web of Science ®Google Scholar
• Labios M, Martinez M, Gabriel F, Gomez-Biedma S, Guiral V, Vivo M, Aznar J. Flow cytometric analysis of platelet activation in hypertensive patients. Effect of doxazosin. Thromb Res 2003;110:203–208
   PubMed Web of Science ®Google Scholar
• Berlot CH. Expression and functional analysis of G protein alpha subunits in S49 lymphoma cells. Methods Enzymol 2002;344:261–277
   PubMed Web of Science ®Google Scholar
• Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002;99:193–198
   PubMed Web of Science ®Google Scholar
• Cho MJ, Liu J, Pestina TI, Steward SA, Jackson CW, Gartner TK. AlphaIIbbeta3-mediated outside-in signaling induced by the agonist peptide LSARLAF utilizes ADP and thromboxane A2 receptors to cause alpha-granule secretion by platelets. J Thromb Haemost 2003;1:363–373
   PubMed Web of Science ®Google Scholar
• Merritt JE, McCarthy SA, Davies MP, Moores KE. Use of fluo-3 to measure cytosolic Ca2+ in platelets and neutrophils. Loading cells with the dye, calibration of traces, measurements in the presence of plasma, and buffering of cytosolic Ca2+. Biochem J 1990;269:513–519
   PubMed Web of Science ®Google Scholar
• Pan C, Wei X, Ye J, Liu G, Zhang S, Zhang Y, Du H, Ding Z. BF066, a novel dual target antiplatelet agent without significant bleeding. PLoS One 2012;7:e40451
   PubMed Web of Science ®Google Scholar
• Su X, Mi J, Yan J, Flevaris P, Lu Y, Liu H, Ruan Z, Wang X, Kieffer N, Chen S, et al. RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood 2008;112:592–602
   PubMed Web of Science ®Google Scholar
• Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 2011;121:4462–4476
   PubMed Web of Science ®Google Scholar
• Shankar H, Kahner BN, Prabhakar J, Lakhani P, Kim S, Kunapuli SP. G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. Blood 2006;108:3027–3034
   PubMed Web of Science ®Google Scholar
• Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost 2012;10:167–176
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Newman PJ. Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood 2004;104:1606–1615
   PubMed Web of Science ®Google Scholar
• Wang X, Li Y, Zhao Q, Min Z, Zhang C, Lai Y, Ji H, Peng S, Zhang Y. Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents. Org Biomol Chem 2011;9:5670–5681
   PubMed Web of Science ®Google Scholar